citalopram has been researched along with Mental Disorders in 51 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." | 9.17 | Prevention of poststroke apathy using escitalopram or problem-solving therapy. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2013) |
| "To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder (OCD) patients." | 9.14 | Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. ( Denys, D; Fluitman, SB; Meinardi, JC; Vulink, NC; Westenberg, HG, 2009) |
| "There was no major effect of inflammation on the metabolism of citalopram and venlafaxine." | 7.81 | Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2015) |
| "Escitalopram, which is a recently marketed selective serotonin reuptake inhibitors (SSRI), has no such reputation." | 5.33 | Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. ( Akarsu, ES; Ayhan, IH; Cankurtaran, ES; Cekic, T; Ozalp, E; Palaoglu, O; Soygur, H; Turhan, L, 2006) |
| "Escitalopram or PST was significantly more effective in preventing new onset of apathy following stroke compared with placebo." | 5.17 | Prevention of poststroke apathy using escitalopram or problem-solving therapy. ( Arndt, S; Fonzetti, P; Hegel, MT; Jang, M; Jorge, RE; Mikami, K; Moser, DJ; Robinson, RG; Small, SL; Solodkin, A, 2013) |
| "To assess the efficacy of quetiapine addition to citalopram in treatment-naive or medication-free obsessive-compulsive disorder (OCD) patients." | 5.14 | Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients. ( Denys, D; Fluitman, SB; Meinardi, JC; Vulink, NC; Westenberg, HG, 2009) |
| " They also suggest that lithium for comorbid bipolar disorder, escitalopram for comorbid anxiety disorders, and the addition of CBT to standard drug treatment for comorbid schizophrenia may be effective." | 4.93 | Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research. ( Dowling, NA; Lorains, FK; Merkouris, SS, 2016) |
| "There was no major effect of inflammation on the metabolism of citalopram and venlafaxine." | 3.81 | Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2015) |
| "To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients." | 3.75 | Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. ( Hynan, LS; Siddique, H; Weiner, MF, 2009) |
| " To compare the effects of antidepressant drugs, the electrocardiogram (ECG), vectorcardiogram (VCG), and body surface maps (BSM) were recorded in psychiatric patients without cardiovascular diseases treated by a) TCA amitriptyline or dosulepin (daily dose 50-200 mg, 22 patients), b) lithium (serum level 0." | 3.70 | Antidepressant drugs and heart electrical field. ( Hamplová, J; Horácek, BM; Kittnar, O; Paclt, I; Slavícek, J; Trefný, Z, 1998) |
| "In patients with Alzheimer's disease and vascular dementia, there are symptoms not only of cognitive impairment but also of emotional disturbance." | 2.67 | Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. ( Gottfries, CG; Nyth, AL, 1991) |
| "Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders." | 2.52 | Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. ( Cummings, J; Zhong, K, 2015) |
| "Emphasis is given to the treatment of depression and how the potential of one pure enantiomer-escitalopram, the S-enantiomer of the selective serotonin reuptake inhibitor citalopram-appears to be fulfilling its preclinical promise in the clinic." | 2.41 | Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. ( Baumann, P; Eap, CB; Zullino, DF, 2002) |
| "Sudden cardiac death was recorded in five patients, and torsade de pointes was recorded in seven other patients." | 1.39 | Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. ( Berney, P; Dayer, P; Gaspoz, JM; Gex-Fabry, M; Girardin, FR; Shah, D, 2013) |
| "Risperidone (N=45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%)." | 1.35 | Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. ( Alacqua, M; Arcoraci, V; Calarese, T; Di Vita, G; Gagliano, C; Germanò, E; Magazù, A; Spina, E; Trifirò, G, 2008) |
| "Citalopram was the most preferred antidepressant and Carbamazepine, the most preferred mood stabilizer/antiepileptic." | 1.35 | Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey. ( Deb, S; Unwin, GL, 2008) |
| "Baclofen and oxazepam were prescribed secondary to right-sided hemiparesis contractures." | 1.34 | Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities. ( Brahm, NC; Brown, RC; McElwain, DL, 2007) |
| "Escitalopram, which is a recently marketed selective serotonin reuptake inhibitors (SSRI), has no such reputation." | 1.33 | Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report. ( Akarsu, ES; Ayhan, IH; Cankurtaran, ES; Cekic, T; Ozalp, E; Palaoglu, O; Soygur, H; Turhan, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.96) | 18.7374 |
| 1990's | 6 (11.76) | 18.2507 |
| 2000's | 24 (47.06) | 29.6817 |
| 2010's | 20 (39.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hughes, S | 1 |
| Lacasse, J | 1 |
| Fuller, RR | 1 |
| Spaulding-Givens, J | 1 |
| Ebert, K | 1 |
| Maurice, E | 1 |
| Lukačin, R | 1 |
| Fleischhaker, C | 1 |
| Schulz, E | 1 |
| Ebert, D | 1 |
| Clement, HW | 1 |
| Canbolat, F | 1 |
| Tasdemir Erinç, DM | 1 |
| Evrensel, A | 1 |
| Aydın, A | 1 |
| Tarhan, KN | 1 |
| Maruf, AA | 1 |
| Greenslade, A | 1 |
| Arnold, PD | 1 |
| Bousman, C | 1 |
| Lam, D | 1 |
| Gorman, DA | 1 |
| Patten, S | 1 |
| Pringsheim, T | 1 |
| Mikami, K | 1 |
| Jorge, RE | 1 |
| Moser, DJ | 1 |
| Arndt, S | 1 |
| Jang, M | 1 |
| Solodkin, A | 1 |
| Small, SL | 1 |
| Fonzetti, P | 1 |
| Hegel, MT | 1 |
| Robinson, RG | 1 |
| Stock, EM | 1 |
| Copeland, LA | 1 |
| Bush, RL | 1 |
| Zeber, JE | 1 |
| Girardin, FR | 1 |
| Gex-Fabry, M | 1 |
| Berney, P | 1 |
| Shah, D | 1 |
| Gaspoz, JM | 1 |
| Dayer, P | 1 |
| Nemoto, K | 1 |
| Mihara, K | 1 |
| Nakamura, A | 1 |
| Nagai, G | 1 |
| Kagawa, S | 1 |
| Suzuki, T | 1 |
| Kondo, T | 1 |
| Cummings, J | 1 |
| Zhong, K | 1 |
| Gioia, S | 1 |
| Lancia, M | 1 |
| Bacci, M | 1 |
| Suadoni, F | 1 |
| Hefner, G | 1 |
| Shams, ME | 1 |
| Unterecker, S | 1 |
| Falter, T | 1 |
| Hiemke, C | 1 |
| Grover, S | 1 |
| Avasthi, A | 1 |
| Tripathi, A | 1 |
| Tanra, AJ | 1 |
| Chee, KY | 1 |
| He, YL | 1 |
| Chiu, HF | 1 |
| Kuga, H | 1 |
| Lee, MS | 1 |
| Chong, MY | 1 |
| Udormatn, P | 1 |
| Kanba, S | 1 |
| Yang, SY | 1 |
| Si, TM | 1 |
| Sim, K | 1 |
| Tan, CH | 1 |
| Shen, WW | 1 |
| Xiang, YT | 1 |
| Sartorius, N | 1 |
| Shinfuku, N | 1 |
| Dowling, NA | 1 |
| Merkouris, SS | 1 |
| Lorains, FK | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Murray, KT | 1 |
| Hall, K | 1 |
| Stein, CM | 1 |
| Siddique, H | 1 |
| Hynan, LS | 1 |
| Weiner, MF | 1 |
| Vulink, NC | 1 |
| Denys, D | 1 |
| Fluitman, SB | 1 |
| Meinardi, JC | 1 |
| Westenberg, HG | 1 |
| Perroud, N | 1 |
| Uher, R | 1 |
| Hauser, J | 1 |
| Rietschel, M | 1 |
| Henigsberg, N | 1 |
| Placentino, A | 1 |
| Kozel, D | 1 |
| Maier, W | 1 |
| Mors, O | 1 |
| Souery, D | 1 |
| Dmitrzak-Weglarz, M | 1 |
| Jorgensen, L | 1 |
| Kovacic, Z | 1 |
| Giovannini, C | 1 |
| Mendlewicz, J | 1 |
| Zobel, A | 1 |
| Strohmaier, J | 1 |
| McGuffin, P | 1 |
| Aitchison, KJ | 1 |
| Farmer, A | 1 |
| Edelmuth, RC | 1 |
| Nitsche, MA | 1 |
| Battistella, L | 1 |
| Fregni, F | 1 |
| Talley, NJ | 1 |
| Herrick, L | 1 |
| Locke, GR | 1 |
| Nutt, DJ | 1 |
| Feetam, CL | 1 |
| Kelley, ME | 1 |
| Franco, AR | 1 |
| Mayberg, HS | 1 |
| Holtzheimer, PE | 1 |
| Baumann, P | 1 |
| Zullino, DF | 1 |
| Eap, CB | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Koran, LM | 3 |
| Dobscha, SK | 1 |
| Anderson, TA | 1 |
| Hoffman, WF | 1 |
| Winterbottom, LM | 1 |
| Turner, EH | 1 |
| Snodgrass, LS | 1 |
| Hauser, P | 1 |
| Aboujaoude, E | 1 |
| Gamel, N | 1 |
| Gabbay, V | 1 |
| Coffey, B | 1 |
| Vaishnavi, SN | 1 |
| Nemeroff, CB | 1 |
| Plott, SJ | 1 |
| Rao, SG | 1 |
| Kranzler, J | 1 |
| Owens, MJ | 1 |
| Trivedi, MH | 2 |
| Rush, AJ | 1 |
| Wisniewski, SR | 1 |
| Nierenberg, AA | 1 |
| Warden, D | 1 |
| Ritz, L | 1 |
| Norquist, G | 1 |
| Howland, RH | 1 |
| Lebowitz, B | 1 |
| McGrath, PJ | 1 |
| Shores-Wilson, K | 1 |
| Biggs, MM | 1 |
| Balasubramani, GK | 1 |
| Fava, M | 1 |
| Sterr, A | 1 |
| Padberg, F | 1 |
| Amann, B | 1 |
| Mergl, R | 1 |
| Mulert, C | 1 |
| Juckel, G | 1 |
| Hegerl, U | 1 |
| Pogarell, O | 1 |
| Ozalp, E | 1 |
| Soygur, H | 1 |
| Cankurtaran, ES | 1 |
| Turhan, L | 1 |
| Cekic, T | 1 |
| Akarsu, ES | 1 |
| Palaoglu, O | 1 |
| Ayhan, IH | 1 |
| Huuhka, K | 1 |
| Riutta, A | 1 |
| Haataja, R | 1 |
| Ylitalo, P | 1 |
| Leinonen, E | 1 |
| Aboujaoude, EN | 1 |
| Solvason, B | 1 |
| Gamel, NN | 1 |
| Smith, EH | 1 |
| Brahm, NC | 1 |
| McElwain, DL | 1 |
| Brown, RC | 1 |
| Alacqua, M | 1 |
| Trifirò, G | 1 |
| Arcoraci, V | 1 |
| Germanò, E | 1 |
| Magazù, A | 1 |
| Calarese, T | 1 |
| Di Vita, G | 1 |
| Gagliano, C | 1 |
| Spina, E | 1 |
| Rudberg, I | 1 |
| Mohebi, B | 1 |
| Hermann, M | 1 |
| Refsum, H | 1 |
| Molden, E | 1 |
| Hergüner, S | 1 |
| Kilinçaslan, A | 1 |
| Görker, I | 1 |
| Tüzün, U | 1 |
| Giacobbe, P | 1 |
| Flint, A | 1 |
| Unwin, GL | 1 |
| Deb, S | 1 |
| Ances, BM | 1 |
| Letendre, SL | 1 |
| Alexander, T | 1 |
| Ellis, RJ | 1 |
| Oyehaug, E | 1 |
| Ostensen, ET | 1 |
| Salvesen, B | 1 |
| Spigset, O | 1 |
| Adielsson, G | 1 |
| Slavícek, J | 1 |
| Paclt, I | 1 |
| Hamplová, J | 1 |
| Kittnar, O | 1 |
| Trefný, Z | 1 |
| Horácek, BM | 1 |
| Stahl, SM | 1 |
| Marston, HM | 1 |
| Reid, ME | 1 |
| Lawrence, JA | 1 |
| Olverman, HJ | 1 |
| Butcher, SP | 1 |
| Ekselius, L | 1 |
| Von Knorring, L | 1 |
| Liechti, ME | 1 |
| Vollenweider, FX | 1 |
| Baker, SM | 1 |
| Perino, C | 1 |
| Rago, R | 1 |
| Cicolini, A | 1 |
| Torta, R | 1 |
| Monaco, F | 1 |
| Enos, G | 1 |
| Gottfries, CG | 1 |
| Nyth, AL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.[NCT02323633] | Phase 2 | 48 participants (Anticipated) | Interventional | 2015-01-31 | Not yet recruiting | ||
| Improving Outcomes of Depression in Primary Care[NCT00105833] | 400 participants (Actual) | Interventional | 2002-07-31 | Completed | |||
| Digital Interventions as an Add-on Tool in Generalized Anxiety Disorder Treatment: A Randomized Clinical Trial[NCT05375851] | 60 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Dallas 2K: A Natural History Study of Depression[NCT02919280] | 2,000 participants (Anticipated) | Observational | 2016-09-30 | Recruiting | |||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Evaluation of Schemes of Administration of Intravenous Ketamine in Treatment-resistant Depression: Clinical-neuroimaging Correlation[NCT03742557] | Phase 3 | 30 participants (Anticipated) | Interventional | 2018-10-01 | Recruiting | ||
| Conscious Dying/Conscious Living: Ketamine-Assisted Psychotherapy (KAP) for Patients at End of Life-A Pilot Study for Palliative and Hospice Care[NCT05214417] | Phase 2 | 120 participants (Anticipated) | Interventional | 2022-05-01 | Not yet recruiting | ||
| Subanesthetic Sevoflurane for Treatment-Resistant Depression: A Proof-of-Concept Trial[NCT05008939] | 15 participants (Anticipated) | Interventional | 2021-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
7 reviews available for citalopram and Mental Disorders
| Article | Year |
|---|---|
Antidepressant pharmacogenetics in children and young adults: A systematic review.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Citalopram; Cytochrome P-450 CYP2C19; Cytoc | 2019 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental | 2015 |
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research.
Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar | 2016 |
Why do some promising brain-stimulation devices fail the next steps of clinical development?
Topics: Animals; Benzothiazoles; Brain; Brain Diseases; Citalopram; Dopamine Agonists; Humans; Mental Disord | 2010 |
Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Fluoxetine; Humans; Menta | 2002 |
Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders.
Topics: Antiretroviral Therapy, Highly Active; Brain; Citalopram; Cognition Disorders; HIV Infections; Human | 2008 |
Clinical significance of monitoring early symptom change to predict outcome.
Topics: Algorithms; Citalopram; Clinical Trials as Topic; Depressive Disorder; Humans; Mental Disorders; Pip | 2001 |
13 trials available for citalopram and Mental Disorders
| Article | Year |
|---|---|
Prevention of poststroke apathy using escitalopram or problem-solving therapy.
Topics: Aged; Antidepressive Agents, Second-Generation; Apathy; Citalopram; Female; Humans; Male; Mental Dis | 2013 |
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
Topics: Adult; Aripiprazole; Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Dr | 2014 |
Quetiapine augments the effect of citalopram in non-refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled study of 76 patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Citalopram; Comorbidity; Diagnostic and Statistical Manual | 2009 |
History of suicide attempts among patients with depression in the GENDEP project.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Citalopram; Comor | 2010 |
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Topics: Adult; Citalopram; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Fema | 2002 |
A 1-year naturalistic follow-up of patients with compulsive shopping disorder.
Topics: Adult; Citalopram; Cohort Studies; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; | 2003 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
Topics: Adolescent; Ambulatory Care; Chronic Disease; Citalopram; Comorbidity; Depressive Disorder, Major; D | 2006 |
The effect of CYP2C19 substrate on the metabolism of melatonin in the elderly: A randomized, double-blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anticonvulsants; Antidepressive Ag | 2006 |
Escitalopram for compulsive buying disorder: a double-blind discontinuation study.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Asian People; Citalopram; Compulsive Behavior | 2007 |
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Citalopram; Cytochro | 2008 |
Changes in personality traits during treatment with sertraline or citalopram.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Female; Huma | 1999 |
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
Topics: Adult; Animals; Blood Pressure; Body Temperature; Citalopram; Cross-Over Studies; Dopamine; Double-B | 2000 |
Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia.
Topics: Alzheimer Disease; Citalopram; Dementia, Vascular; Double-Blind Method; Humans; Mental Disorders; Pl | 1991 |
31 other studies available for citalopram and Mental Disorders
| Article | Year |
|---|---|
Adverse effects and treatment satisfaction among online users of four antidepressants.
Topics: Affective Symptoms; Antidepressive Agents; Citalopram; Duloxetine Hydrochloride; Humans; Internet; M | 2017 |
Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Desvenlafa | 2018 |
Quantitation of escitalopram and its metabolites by liquid chromatography-tandem mass spectrometry in psychiatric patients: New metabolic ratio establishment.
Topics: Adolescent; Adult; Aged; Chromatography, Liquid; Citalopram; Drug Monitoring; Humans; Mental Disorde | 2019 |
The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents; Canada; Child; Child, Preschool; Citalopram; | 2013 |
Datapoints: Prevalence of QT prolongation among veterans with severe mental illness.
Topics: Antidepressive Agents; Citalopram; Humans; Long QT Syndrome; Mental Disorders; Middle Aged; Prevalen | 2013 |
Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Case-Control Studies; Citalopram; Cross-Sectional Stu | 2013 |
A Fatal Case of Acute Butane-Propane Poisoning in a Prisoner Under Psychiatric Treatment: Do These 2 Factors Have an Arrhythmogenic Interaction, Thus Increasing the Cardiovascular Risk Profile?
Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Butanes; Chlorpromazine; Citalopram; Drug Interac | 2015 |
Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; C-Reactive Protein; Citalopram; Female; Human | 2015 |
Antidepressant Prescription Pattern in the Presence of Medical Co-morbidity: REAP-AD 2013 Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; | 2015 |
High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Topics: Adult; Aged; Ambulatory Care; Citalopram; Cohort Studies; Dose-Response Relationship, Drug; Drug The | 2017 |
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Citalopram; Delusions; Drug Therapy, Combination; Hallucina | 2009 |
Antidepressants in functional dyspepsia.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Citalopram; Dyspepsia; Human | 2010 |
What one hand giveth the other taketh away: some unpredicted effects of enantiomers in psychopharmacology.
Topics: Animals; Azabicyclo Compounds; Citalopram; Eszopiclone; Fluoxetine; Humans; Mental Disorders; Molecu | 2010 |
The Illness Density Index (IDI): A longitudinal measure of treatment efficacy.
Topics: Adult; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Depressive Disorder, Major; | 2012 |
Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
Topics: Citalopram; Clinical Pharmacy Information Systems; Cost Control; Cost Savings; Drug Administration S | 2003 |
Obsessive-Compulsive disorder, Tourette's disorder, or pediatric autoimmune neuropsychiatric disorders associated with Streptococcus in an adolescent? Diagnostic and therapeutic challenges.
Topics: Adolescent; Antipsychotic Agents; Autoimmune Diseases; Citalopram; Clinical Laboratory Techniques; D | 2003 |
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Carrier Proteins; Citalopram; Cyclohexanols; Cy | 2004 |
Electroencephalographic abnormalities associated with antidepressant treatment: a comparison of mirtazapine, venlafaxine, citalopram, reboxetine, and amitriptyline.
Topics: Adult; Amitriptyline; Antidepressive Agents; Cerebral Cortex; Citalopram; Cyclohexanols; Electroence | 2006 |
Sertraline, escitalopram and tianeptine related abnormal movements but not with bupropion: a case report.
Topics: Adult; Bupropion; Citalopram; Dopamine Uptake Inhibitors; Dyskinesias; Humans; Male; Mental Disorder | 2006 |
Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Baclofen; Basal Ganglia Diseases; Citalopram; | 2007 |
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Citalopram; Drug Ut | 2008 |
Serotonin-selective reuptake inhibitor-induced enuresis in three pediatric cases.
Topics: Child; Citalopram; Female; Fluvoxamine; Humans; Male; Mental Disorders; Nocturnal Enuresis; Selectiv | 2007 |
Pharmacological treatment of post-stroke pathological laughing and crying.
Topics: Antidepressive Agents; Citalopram; Crying; Humans; Laughter; Male; Mental Disorders; Middle Aged; Se | 2007 |
Use of medication for the management of behavior problems among adults with intellectual disabilities: a clinicians' consensus survey.
Topics: Adult; Aggression; Antipsychotic Agents; Attitude of Health Personnel; Autistic Disorder; Carbamazep | 2008 |
High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients.
Topics: Adult; Aged; Antidepressive Agents; Biotransformation; Chromatography, High Pressure Liquid; Citalop | 1984 |
Combined serotonin syndrome and hyponatraemia caused by a citalopram-buspirone interaction.
Topics: Aged; Buspirone; Citalopram; Depressive Disorder; Drug Interactions; Female; Humans; Hyponatremia; M | 1997 |
Antidepressant drugs and heart electrical field.
Topics: Adult; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiovascular Diseas | 1998 |
Using secondary binding properties to select a not so selective serotonin reuptake inhibitor.
Topics: Adolescent; Adult; Child; Citalopram; Cytochrome P-450 Enzyme System; Drug Prescriptions; Fluoxetine | 1998 |
Behavioural analysis of the acute and chronic effects of MDMA treatment in the rat.
Topics: Animals; Behavior, Animal; Biogenic Monoamines; Chromatography, High Pressure Liquid; Citalopram; Ki | 1999 |
Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management.
Topics: Adult; Antidepressive Agents; Brain Injuries; Brief Psychiatric Rating Scale; Carbamazepine; Citalop | 2001 |
Tapping the potential of isomer science.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Depression; Humans; | 2002 |